Experience with Entecavir Therapy for Lamivudine-Resistant Chronic Hepatitis B in Korean Children and Adolescents.
10.5223/kjpgn.2010.13.1.44
- Author:
Seung Man CHO
1
;
Byung Ho CHOE
;
Mi Ae CHU
;
Jung Mi KIM
Author Information
1. Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea. bhchoi@knu.ac.kr
- Publication Type:Original Article
- Keywords:
Entecavir;
Adefovir;
Lamivudine;
Chronic hepatitis B;
Resistance
- MeSH:
Adenine;
Adolescent;
Child;
DNA;
Follow-Up Studies;
Guanine;
Hepatitis B, Chronic;
Hepatitis, Chronic;
Humans;
Lamivudine;
Organophosphonates
- From:Korean Journal of Pediatric Gastroenterology and Nutrition
2010;13(1):44-50
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To estimate the viral suppressive effect of entecavir monotherapy in Korean children and adolescents with lamivudine-resistant chronic hepatitis B (CHB). METHODS: One milligram of entecavir was administered once daily to 6 patients (4 boys; mean age, 17.5 years; range, 15.10~24.6 years) with lamivudine-resistant CHB for a mean duration of therapy of 13.4 months (range, 1~21.1 months). The therapeutic results were compared with 11 patients who received adefovir (0.3 mg/kg/day [maximal dose 10 mg]) for at least 12 months (mean, 33.4 months; range, 12.4~58.3 months). The serum HBV DNA level and serologic markers were measured every 2 months. RESULTS: The interval to a HBV DNA titer decrement (>1 log(10)) was 1.2+/-0.2 and 4.4+/-5.2 months (p=0.185) for the entecavir and adefovir groups, respectively. The interval to a HBV DNA titer decrement (>2 log(10)) was 2.4+/-2.3 and 9.2+/-7.3 months (p=0.025), for the entecavir and adefovir groups, respectively. CONCLUSION: The therapeutic efficacy of entecavir was favorable in children and adolescents, especially in shortening the interval to a >2 log(10) decrement in the HBV DNA titer. Long-term follow up is needed to determine the therapeutic efficacy of entecavir for lamivudine-resistant CHB in children and adolescents.
